202 related articles for article (PubMed ID: 29209323)
21. Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.
Tjiam MC; Taylor JP; Morshidi MA; Sariputra L; Burrows S; Martin JN; Deeks SG; Tan DB; Lee S; Fernandez S; French MA
J Immunol; 2015 Jun; 194(11):5320-8. PubMed ID: 25911748
[TBL] [Abstract][Full Text] [Related]
22. Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1.
Lewis GK; Finzi A; DeVico AL; Pazgier M
Viruses; 2015 Sep; 7(9):5115-32. PubMed ID: 26393642
[TBL] [Abstract][Full Text] [Related]
23. Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway.
Leopold PL; Wendland RL; Vincent T; Crystal RG
J Virol; 2006 Oct; 80(20):10237-47. PubMed ID: 17005701
[TBL] [Abstract][Full Text] [Related]
24. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
[TBL] [Abstract][Full Text] [Related]
25. Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses.
Wren LH; Stratov I; Kent SJ; Parsons MS
Vaccine; 2013 Nov; 31(47):5506-17. PubMed ID: 23981432
[TBL] [Abstract][Full Text] [Related]
26. Post-infection immunodeficiency virus control by neutralizing antibodies.
Yamamoto H; Kawada M; Takeda A; Igarashi H; Matano T
PLoS One; 2007 Jun; 2(6):e540. PubMed ID: 17579714
[TBL] [Abstract][Full Text] [Related]
27. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model.
Rotman HL; Daly TM; Clynes R; Long CA
J Immunol; 1998 Aug; 161(4):1908-12. PubMed ID: 9712060
[TBL] [Abstract][Full Text] [Related]
28. Fc receptor but not complement binding is important in antibody protection against HIV.
Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
[TBL] [Abstract][Full Text] [Related]
29. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.
Kim JH; Mascola JR; Ratto-Kim S; VanCott TC; Loomis-Price L; Cox JH; Michael NL; Jagodzinski L; Hawkes C; Mayers D; Gilliam BL; Birx DC; Robb ML
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1021-34. PubMed ID: 11485619
[TBL] [Abstract][Full Text] [Related]
30. Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies.
Sun M; Li Y; Zheng H; Shao Y
Front Immunol; 2016; 7():391. PubMed ID: 27746780
[TBL] [Abstract][Full Text] [Related]
31. Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".
Sun Z; Li J; Hu X; Shao Y; Zhang MY
Antiviral Res; 2015 Jun; 118():1-9. PubMed ID: 25770672
[TBL] [Abstract][Full Text] [Related]
32. Single-Administration Long-Acting Microarray Patch with Ultrahigh Loading Capacity and Multiple Releases of Thermally Stable Antibodies.
Tran KTM; Le TT; Agrahari V; Peet MM; Ouattara LA; Anderson SM; Le-Kim TH; Singh ON; Doncel GF; Nguyen TD
Mol Pharm; 2023 May; 20(5):2352-2361. PubMed ID: 37014806
[TBL] [Abstract][Full Text] [Related]
33. Conserved HIV Epitopes for an Effective HIV Vaccine.
Sahay B; Nguyen CQ; Yamamoto JK
J Clin Cell Immunol; 2017 Aug; 8(4):. PubMed ID: 29226015
[TBL] [Abstract][Full Text] [Related]
34. Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains.
Joyce MG; Georgiev IS; Yang Y; Druz A; Geng H; Chuang GY; Kwon YD; Pancera M; Rawi R; Sastry M; Stewart-Jones GBE; Zheng A; Zhou T; Choe M; Van Galen JG; Chen RE; Lees CR; Narpala S; Chambers M; Tsybovsky Y; Baxa U; McDermott AB; Mascola JR; Kwong PD
Cell Rep; 2017 Dec; 21(10):2992-3002. PubMed ID: 29212041
[TBL] [Abstract][Full Text] [Related]
35. HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.
Herbeck JT; Peebles K; Edlefsen PT; Rolland M; Murphy JT; Gottlieb GS; Abernethy N; Mullins JI; Mittler JE; Goodreau SM
Vaccine; 2018 Jan; 36(4):514-520. PubMed ID: 29241646
[TBL] [Abstract][Full Text] [Related]
36. The molecular immune modulator adenosine deaminase-1 enhances HIV specific humoral and cellular responses to a native-like HIV envelope trimer DNA vaccine.
Kutzler MA; Cusimano G; Joyner D; Konopka E; Muir R; Barnette P; Guderian M; Del Moral-Sánchez I; Derking R; Bijl T; Snitselaar J; Rotsides P; Woloszczuk K; Bell M; Canziani G; Chaiken I; Hessell A; Bartsch Y; Sanders R; Haddad E
Res Sq; 2024 Apr; ():. PubMed ID: 38746176
[TBL] [Abstract][Full Text] [Related]
37. Beyond bNAbs: Uses, Risks, and Opportunities for Therapeutic Application of Non-Neutralising Antibodies in Viral Infection.
Mader K; Dustin LB
Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38651408
[TBL] [Abstract][Full Text] [Related]
38. An Overview of the Use of Nanoparticles in Vaccine Development.
Lozano D; Larraga V; Vallet-Regí M; Manzano M
Nanomaterials (Basel); 2023 Jun; 13(12):. PubMed ID: 37368258
[TBL] [Abstract][Full Text] [Related]
39. Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2.
Alcolea PJ; Larraga J; Rodríguez-Martín D; Alonso A; Loayza FJ; Rojas JM; Ruiz-García S; Louloudes-Lázaro A; Carlón AB; Sánchez-Cordón PJ; Nogales-Altozano P; Redondo N; Manzano M; Lozano D; Palomero J; Montoya M; Vallet-Regí M; Martín V; Sevilla N; Larraga V
Front Immunol; 2022; 13():1023255. PubMed ID: 36439169
[TBL] [Abstract][Full Text] [Related]
40. One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines.
Ilchmann H; Samy N; Reichhardt D; Schmidt D; Powell JD; Meyer TPH; Silbernagl G; Nichols R; Weidenthaler H; De Moerlooze L; Chen L; Chaplin P
J Infect Dis; 2023 May; 227(10):1203-1213. PubMed ID: 36408618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
